Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Podcast with prof. Michael Boyer about the phase III Keynote 598 study of ipilimumab and pembrolizumab
    vs. pembrolizumab monotherapy, in metastatic non-small cell lung cancer

2. PD-L1 expression determines the level of clinical benefit derived from first-line cemiplimab in patients
    with advanced non-small cell lung cancer

3. Nivolumab for pre-treated malignant pleural mesothelioma patients: real world evidence

4. Promising activity of poziotinib in previously treated NSCLC patients with EGFR or HER2 exon 20 mutations

5. Highly encouraging anti-tumour activity of the TROP-2 directed antibody drug conjugate datopotamab
    deruxtecan in heavily pre-treated advanced NSCLC patients